- $669.93m
- $346.09m
Brief: Aura Biosciences Reports First Quarter 2023 Financial Results
Brief: Aura Biosciences Reports Q4 And Full Year 2022 Financial Results And Provides Clinical Development And Operational Highlights
Brief: Aura Biosciences Announces Positive Interim Phase 2 Safety And Efficacy Data Of Belzupacap Sarotalocan (Bel-Sar) For The First-Line Treatment Of Patients With Early-Stage Choroidal Melanoma With Suprachoroidal Administration
U.S. STOCKS ON THE MOVE-Silver miners, PVH Corp, energy firms
Aura Biosciences slips after pricing public offering
Brief: Aura Biosciences Announces Pricing Of Public Offering Of Common Stock At $12.00 Per Share
Brief: Aura Biosciences Announces Proposed Public Offering Of Common Stock
Brief: Aura Announces Global Phase 3 Trial Design With Suprachoroidal Route
Brief: Aura Biosciences Reports Q3 2022 Results
Brief: Aura Biosciences Says Belzupacap Sarotalocan Offers Favorable Safety Profile
U.S. STOCKS ON THE MOVE-Heartbeam, Aura Biosciences, U.S. banks
Aura Biosciences jumps as dosing begins in cancer drug study
Brief: Aura Biosciences Announces First Patient Dosed In Early-Stage Study Of Non-Muscle Invasive Bladder Cancer Treatment Candidate
Brief: Aura Biosciences To Present Phase 2 Safety Data Evaluating Suprachoroidal Administration Of Belzupacap Sarotalocan (Au-011) In Patients With Choroidal Melanoma At Esmo 2022 Congress
Brief: Aura Biosciences Reports Q2 Net Loss $13.5 Million
U.S. STOCKS ON THE MOVE-Walgreens, Enjoy Technology, Aura Biosciences, Goldman
U.S. STOCKS ON THE MOVE-Alphabet, Boeing, iRobot, Enjoy Tech
Aura Bio rises on FDA fast track tag for bladder cancer treatment
Brief: Aura Biosciences Receives FDA Fast Track Designation For Treatment Of Non-Muscle Invasive Bladder Cancer